Kai Huang

7PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 28, 2023
Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radioligand Therapy.

Sebastian Gaal, Kai Huang, Julian M M Rogasch

|Jun 24, 2022
Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.

Kevin Zwirtz, Juliane Hardt, Güliz Acker

|Apr 12, 2022
Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC.

Markus Galler, Julian M M Rogasch, Kai Huang

|Aug 07, 2021
Sentinel Lymph Node Biopsy in Early Stages of Oral Squamous Cell Carcinoma Using the Receptor-Targeted Radiotracer 99mTc-Tilmanocept.

Christian Doll, Claudius Steffen, Holger Amthauer

|Feb 10, 2021
The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis.

Tristan Ruhwedel, Julian M M Rogasch, Kai Huang

|Dec 22, 2020
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen.

Kai Huang, Imke Schatka, Julian M M Rogasch

Pageof 2

Frequent Collaborators

5 joint publications

Holger Amthauer

3 joint publications

Julian M M Rogasch

2 joint publications

Christoph Wetz

1 joint publications

Josefine Graef